Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma

GAITHERSBURG, Md., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product De... Biopharmaceuticals, Oncology, FDA Sirnaomics, Cholangiocarcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news